Real-World Outcomes of Brexucabtagene Autoleucel (Brexu-cel) in Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia: A Single-Center Experience from Saudi Arabia

Key Points

• Treatment with brexucabtagene autoleucel shows improved responses in relapsed cases of leukemia, enhancing patient prospects.
• The study reports an impressive overall response rate of 73%, highlighting substantial effectiveness in managing a tough condition.
• Assessment utilized a single-center experience focusing on patient responses to brexucabtagene autoleucel in Saudi Arabia's healthcare setting.
• Findings suggest meaningful clinical benefits, though future multicenter studies are needed for broader applicability.